An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
A phase 3 trial of Talimogene laherparepvec in Melanoma, run by BioVex Limited, completed.
Overview
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma is a phase 3 interventional study registered as NCT01368276 by BioVex Limited, with 31 participants recorded, started 2010-10 and reaching its primary completion in 2014-09. Interventions recorded: Talimogene Laherparepvec, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF). Conditions recorded: Melanoma.
Linked to the drug Talimogene laherparepvec because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialPembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
Shares Talimogene laherparepvec, Amgen, Melanoma and the tag pipeline.
- TrialEfficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
Shares Talimogene laherparepvec, Amgen, Melanoma and the tag pipeline.
- TrialStudy of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
Shares Amgen and the tag pipeline.
- TrialA Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Shares Amgen and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialA Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Shares Amgen and the tag pipeline.
- TrialACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer
Shares Amgen and the tag pipeline.
- TrialA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
Shares Amgen and the tag pipeline.